Edwards Lifesciences Corporation (BIT:1EW)
Italy · Delayed Price · Currency is EUR 66.14
+0.79 (1.21%)
At close: Feb 11, 2026
Edwards Lifesciences Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 6,068 | 5,440 | 5,010 | 4,464 | 5,233 | |
Revenue Growth (YoY) | 11.55% | 8.57% | 12.23% | -14.69% | 19.29% |
Cost of Revenue | 1,334 | 1,118 | 978.4 | 722.1 | 1,249 |
Gross Profit | 4,733 | 4,322 | 4,032 | 3,742 | 3,984 |
Selling, General & Admin | 2,085 | 1,789 | 1,581 | 1,357 | 1,494 |
Research & Development | 1,079 | 1,053 | 962.9 | 843.6 | 903.1 |
Other Operating Expenses | -67.2 | -0.3 | - | - | - |
Operating Expenses | 3,097 | 2,841 | 2,544 | 2,200 | 2,397 |
Operating Income | 1,636 | 1,481 | 1,487 | 1,542 | 1,587 |
Interest Expense | - | -19.8 | -17.6 | -19.2 | -18.4 |
Interest & Investment Income | 148.4 | 120.3 | 67.2 | 35.5 | 17.4 |
Currency Exchange Gain (Loss) | - | 7.1 | 10 | 1 | 5 |
Other Non Operating Income (Expenses) | 7.2 | 6.8 | 3.4 | - | 10.8 |
EBT Excluding Unusual Items | 1,792 | 1,595 | 1,550 | 1,559 | 1,601 |
Merger & Restructuring Charges | -17.4 | -61 | - | -62.3 | - |
Gain (Loss) on Sale of Investments | - | 54.4 | -0.7 | -1.1 | -2.8 |
Asset Writedown | -186.9 | - | - | - | - |
Legal Settlements | -325.4 | -40.4 | -203.5 | -15.8 | -20.6 |
Other Unusual Items | 10.8 | - | 26.2 | 35.8 | 124.1 |
Pretax Income | 1,273 | 1,548 | 1,372 | 1,520 | 1,702 |
Income Tax Expense | 216.9 | 152.1 | 152.4 | 195.5 | 198.9 |
Earnings From Continuing Operations | 1,056 | 1,396 | 1,220 | 1,324 | 1,503 |
Earnings From Discontinued Operations | 13.4 | 2,774 | 179.4 | 197.9 | - |
Net Income to Company | 1,069 | 4,170 | 1,399 | 1,522 | 1,503 |
Minority Interest in Earnings | 4.1 | 4.9 | 3 | - | - |
Net Income | 1,074 | 4,175 | 1,402 | 1,522 | 1,503 |
Net Income to Common | 1,074 | 4,175 | 1,402 | 1,522 | 1,503 |
Net Income Growth | -74.28% | 197.68% | -7.85% | 1.25% | 82.55% |
Shares Outstanding (Basic) | 585 | 598 | 607 | 619 | 623 |
Shares Outstanding (Diluted) | 586 | 599 | 609 | 624 | 631 |
Shares Change (YoY) | -2.25% | -1.66% | -2.37% | -1.11% | -0.11% |
EPS (Basic) | 1.84 | 6.98 | 2.31 | 2.46 | 2.41 |
EPS (Diluted) | 1.83 | 6.97 | 2.30 | 2.44 | 2.38 |
EPS Growth | -73.70% | 202.39% | -5.44% | 2.40% | 83.08% |
Free Cash Flow | - | 289.9 | 642.8 | 973.6 | 1,406 |
Free Cash Flow Per Share | - | 0.48 | 1.05 | 1.56 | 2.23 |
Gross Margin | 78.01% | 79.46% | 80.47% | 83.82% | 76.13% |
Operating Margin | 26.97% | 27.22% | 29.69% | 34.54% | 30.32% |
Profit Margin | 17.69% | 76.75% | 27.99% | 34.09% | 28.73% |
Free Cash Flow Margin | - | 5.33% | 12.83% | 21.81% | 26.88% |
EBITDA | 1,788 | 1,636 | 1,632 | 1,681 | 1,721 |
EBITDA Margin | 29.47% | 30.07% | 32.58% | 37.67% | 32.90% |
D&A For EBITDA | 151.87 | 155.2 | 144.9 | 139.6 | 134.8 |
EBIT | 1,636 | 1,481 | 1,487 | 1,542 | 1,587 |
EBIT Margin | 26.97% | 27.22% | 29.69% | 34.54% | 30.32% |
Effective Tax Rate | 17.04% | 9.83% | 11.11% | 12.87% | 11.69% |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.